Abstract:Significance: Hepatocellular carcinoma (HCC) is a liver malignancy with high mortality rate, limited treatment options and poor prognosis. Sorafenib has been the only systemic treatment option for patients with advanced HCC for more than a decade. While HCC is a typical inflammation-related tumor with distinct immunosuppressive microenvironment especially the up-regulation of immune checkpoints. Recent advances: Immunotherapy has shown persistent and powerful efficacy in HCC treatment. Several preclinical and clinical studies have prompted the application of immunotherapy in first-line, second-line and post-line treatment of HCC, which has profoundly shifted the paradigm for advanced HCC treatment in the past few years. Critical issues and Future directions: Major unaddressed challenges in HCC immunotherapy include the discovery and validation of biological markers that predict the efficacy, the application of immunotherapy in patients with impaired liver function and non-alcoholic steatohepatitis associated-HCC (NASH-HCC), and the exploration of immunotherapy combinations with better effectiveness. This review provides the latest advances in the research of immune microenvironment and immunotherapy in HCC.

Emerging insights on immunotherapy in liver cancer